Role of endogenous hydrogen sulfide in cardiac mitochondrial preservation during ischemia reperfusion injury - 31/12/17
pages | 9 |
Iconographies | 9 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Cardio-protective effect of hydrogen sulfide (H2S) against myocardial ischemia reperfusion injury (I/R) via preservation of mitochondria is well documented. But the distinct role of exogenous and endogenous H2S in cardio-protection and its dependency on functional cardiac mitochondria is not understood. The present study was designed to investigate the role of exogenous H2S preconditioning on cardiac mitochondrial subpopulation namely interfibrillar (IFM) and subsarcolemmal (SSM), in attenuating I/R injury in an isolated rat heart model in the absence of endogenous H2S production. The well-known inhibitor of endogenous H2S production DL-propargylglycine (cystathionine gamma lyase inhibitor) used for this purpose. Our previous studies revealed that NaSH (a H2S donor) preconditioning at a dose of 20μM significantly reduced the infarct size and preserved the functional activities of IFM. However, this protective effect significantly declined, when the heart preconditioned with NaSH in the presence of PAG. Apparently, cardiac recovery was improved hemodynamically to a minimal level by increased concentration of NaSH (40μM). The rat heart perfused with 2, 4 dinitrophenol a mitochondrial uncoupler, before NaSH preconditioning to understand the mitochondrial dependency of exogenous NaSH, we found that cardio-protective effect of NaSH was negated even with higher concentration of H2S. The result indicates that exogenous NaSH mediated cardio protection depends on functional cardiac mitochondria. However, no functional difference between the subpopulation i.e., interfibrillar and subsarcolemmal mitochondria observed with NaSH preconditioning in the presence of PAG.
Le texte complet de cet article est disponible en PDF.Abbreviations : I/R, IFM, SSM, DNP, CSE, PAG
Keywords : Hydrogen sulfide preconditioning, Myocardial ischemia reperfusion, Propargyl glycine, 2,4-Dinitrophenol
Plan
Vol 97
P. 271-279 - janvier 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?